Literature DB >> 21744292

Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension.

Pablo Lobo Martínez1, Ignacio Oulego Erroz, Sandra Gautreux Minaya, Luis Miguel Rodríguez Fernández.   

Abstract

The clinical and hemodynamic effects of compassionate therapy with levosimendan were evaluated in a 14-year-old patient with end-stage renal disease and arterial hypertension secondary to glycogenosis type Ia. The patient previously had normal heart function but experienced acute development of severe myocardial dysfunction resistant to diuretic therapy and inotropic support. Levosimendan administration was followed by a marked clinical and echocardiographic improvement. The authors believe that levosimendan may be useful for cases of resistant acute heart failure with arterial hypertension. Although administration of levosimendan is not recommended for patients with chronic renal disease, no adverse effect was observed. Therapeutic action for these patients seems to last longer than for patients with a normal kidney.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744292     DOI: 10.1007/s00246-011-0041-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

1.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

Authors:  M S Nieminen; J Akkila; G Hasenfuss; F X Kleber; L A Lehtonen; V Mitrovic; O Nyquist; W J Remme
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  Initial experience with levosimendan infusion for preoperative management of hypoplastic left heart syndrome.

Authors:  Luca Di Chiara; Zaccaria Ricci; Cristiana Garisto; Stefano Morelli; Chiara Giorni; Vincenzo Vitale; Roberto M Di Donato; Sergio Picardo
Journal:  Pediatr Cardiol       Date:  2010-01       Impact factor: 1.655

Review 3.  Evidence-based use of levosimendan in different clinical settings.

Authors:  Leonardo De Luca; Wilson S Colucci; Markku S Nieminen; Barry M Massie; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2006-04-27       Impact factor: 29.983

4.  Myocardial efficiency during levosimendan infusion in congestive heart failure.

Authors:  H Ukkonen; M Saraste; J Akkila; J Knuuti; M Karanko; H Iida; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

5.  The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.

Authors:  Catherine Avgeropoulou; Ioanna Andreadou; Sophia Markantonis-Kyroudis; Maritina Demopoulou; Platon Missovoulos; Aris Androulakis; Ioannis Kallikazaros
Journal:  Eur J Heart Fail       Date:  2005-08       Impact factor: 15.534

6.  Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.

Authors:  M T Slawsky; W S Colucci; S S Gottlieb; B H Greenberg; E Haeusslein; J Hare; S Hutchins; C V Leier; T H LeJemtel; E Loh; J Nicklas; D Ogilby; B N Singh; W Smith
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

7.  Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.

Authors:  Michael M Givertz; Costa Andreou; Chester H Conrad; Wilson S Colucci
Journal:  Circulation       Date:  2007-03-05       Impact factor: 29.690

8.  The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.

Authors:  H Yokoshiki; Y Katsube; M Sunagawa; N Sperelakis
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

9.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

Authors:  F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

10.  Sustained hemodynamic effects of intravenous levosimendan.

Authors:  Matti Kivikko; Lasse Lehtonen; Wilson S Colucci
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

View more
  2 in total

1.  Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure.

Authors:  Yan-Zhong Xie; Jian-Ming Ni; Shan-Jing Zhang; Guo-Rong Ding; Jun-Fei Feng
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 2.  Levosimendan in critical illness: a literature review.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Federico Franchi; Luigi Muzzi; Menelaos Karanikolas; Sabino Scolletta
Journal:  J Clin Med Res       Date:  2014-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.